留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

青少年局限性硬皮病发病机制及治疗研究进展

杨婧懿 徐倩玥 余红

杨婧懿, 徐倩玥, 余红. 青少年局限性硬皮病发病机制及治疗研究进展[J]. 协和医学杂志, 2022, 13(1): 110-116. doi: 10.12290/xhyxzz.2021-0178
引用本文: 杨婧懿, 徐倩玥, 余红. 青少年局限性硬皮病发病机制及治疗研究进展[J]. 协和医学杂志, 2022, 13(1): 110-116. doi: 10.12290/xhyxzz.2021-0178
YANG Jingyi, XU Qianyue, YU Hong. Research Progress on Pathogenesis and Treatment of Juvenile Localized Scleroderma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 110-116. doi: 10.12290/xhyxzz.2021-0178
Citation: YANG Jingyi, XU Qianyue, YU Hong. Research Progress on Pathogenesis and Treatment of Juvenile Localized Scleroderma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 110-116. doi: 10.12290/xhyxzz.2021-0178

青少年局限性硬皮病发病机制及治疗研究进展

doi: 10.12290/xhyxzz.2021-0178
详细信息
    通讯作者:

    余红, E-mail:yuhong@xinhuamed.com.cn

  • 中图分类号: R246.7; R593.25

Research Progress on Pathogenesis and Treatment of Juvenile Localized Scleroderma

More Information
  • 摘要: 青少年局限性硬皮病(juvenile localized scleroderma,JLS)是一种罕见的儿童自身免疫性疾病,早期缺乏特异性症状,易被误诊、漏诊而导致病变加剧,甚至造成机体功能损害和生长障碍等严重后果。为明确JLS病因,指导有效治疗药物的开发和应用,本文综述近年来JLS发病机制相关学说,总结其传统治疗方案和相关新型治疗药物研究进展,以提高临床医生对JLS的认识。
    作者贡献:杨婧懿负责查阅文献资料和撰写论文;徐倩玥参与整理文献和修订论文;余红负责指导和修订论文。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis[J]. Pediatr Clin North Am, 2018, 65: 757-781. doi:  10.1016/j.pcl.2018.04.002
    [2] Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study[J]. Rheumatology (Oxford), 2006, 45: 614-620. doi:  10.1093/rheumatology/kei251
    [3] Li SC, Zheng RJ. Overview of Juvenile localized scleroderma and its management[J]. World J Pediatr, 2020, 16: 5-18. doi:  10.1007/s12519-019-00320-9
    [4] Jue MS, Kim MH, Ko JY, et al. Digital image processing for the acquisition of graphic similarity of the distributional patterns between cutaneous lesions of linear scleroderma and Blaschko's lines[J]. J Dermatol, 2011, 38: 778-783. doi:  10.1111/j.1346-8138.2010.01162.x
    [5] Khatri S, Liu C, Mirizio E, et al. Autoantibodies in morphea: An update[J]. Front Immunol, 2019, 10: 1487. doi:  10.3389/fimmu.2019.01487
    [6] Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of Pediatric Localized Scleroderma[J]. Front Immunol, 2019, 10: 908. doi:  10.3389/fimmu.2019.00908
    [7] Walker D, Susa JS, Currimbhoy S, et al. Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort Ⅴ[J]. J Am Acad Dermatol, 2017, 76: 1124-1130. doi:  10.1016/j.jaad.2016.12.020
    [8] Stern EP, Denton CP. The Pathogenesis of Systemic Sclerosis[J]. Rheum Dis Clin North Am, 2015, 41: 367-382. doi:  10.1016/j.rdc.2015.04.002
    [9] Mirizio E, Marathi A, Hershey N, et al. Identifying the Signature Immune Phenotypes Present in Pediatric Localized Scleroderma[J]. J Invest Dermatol, 2019, 139: 715-178. doi:  10.1016/j.jid.2018.09.025
    [10] Torok KS, Kurzinski K, Kelsey C, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles[J]. Semin Arthritis Rheum, 2015, 45: 284-293. doi:  10.1016/j.semarthrit.2015.06.006
    [11] O'Brien JC, Rainwater YB, Malviya N, et al. Transcrip-tional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea[J]. J Invest Dermatol, 2017, 137: 1663-1670. doi:  10.1016/j.jid.2017.04.008
    [12] Uziel Y, Feldman BM, Krafchik BR, et al. Increased serum levels of TGFbeta1 in children with localized scleroderma[J]. Pediatr Rheumatol Online J, 2007, 5: 22. doi:  10.1186/1546-0096-5-22
    [13] Budzyńska-Włodarczyk J, Michalska-Jakubus MM, Kowal M, et al. Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma[J]. Postepy Dermatol Alergol, 2016, 33: 47.
    [14] Kaushik A, Mahajan R, De D, et al. Paediatric morphoea: a holistic review. Part 1: epidemiology, aetiopathogenesis and clinical classification[J]. Clin Exp Dermatol, 2020, 45: 673-678. doi:  10.1111/ced.14234
    [15] 黄婧, 李梦涛, 曾小峰. 药物诱导硬皮病[J]. 协和医学杂志, 2014, 5: 192-196. doi:  10.3969/j.issn.1674-9081.2014.02.014

    Huang J, Li MT, Zeng XF. Drug-induced scleroderma[J]. Xiehe Yixue Zazhi, 2014, 5: 192-196. doi:  10.3969/j.issn.1674-9081.2014.02.014
    [16] Saracino AM, Denton CP, Orteu CH. The molecular pathogenesis of morphoea: from genetics to future treatment targets[J]. Br J Dermatol, 2017, 177: 34-46. doi:  10.1111/bjd.15001
    [17] Condie D, Grabell D, Jacobe H. Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort[J]. Arthritis Rheumatol, 2014, 66: 3496-3504. doi:  10.1002/art.38853
    [18] Foeldvari I. Update on the Systemic Treatment of Pediatric Localized Scleroderma[J]. Paediatr Drugs, 2019, 21: 461-467. doi:  10.1007/s40272-019-00363-5
    [19] Constantin T, Foeldvari I, Pain CE, et al. Development of minimum standards of care for juvenile localized scleroderma[J]. Eur J Pediatr, 2018, 177: 961-977. doi:  10.1007/s00431-018-3144-8
    [20] Do N, Ringold S, Sullivan E, et al. A retrospective study: Impact of consensus treatment plans on systemic therapy of pediatric morphea[J]. Pediatr Dermatol, 2020, 37: 278-283. doi:  10.1111/pde.14074
    [21] Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma[J]. Ann Rheum Dis, 2019, 78: 1019-1024. doi:  10.1136/annrheumdis-2018-214697
    [22] Fett N, Werth VP. Update on morphea: part Ⅱ. Outcome measures and treatment[J]. J Am Acad Dermatol, 2011, 64: 231-244. doi:  10.1016/j.jaad.2010.05.046
    [23] Hardy J, Boralevi F, Mallet S, et al. Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma[J]. Acta Derm Venereol, 2019, 99: 539-543. doi:  10.2340/00015555-3155
    [24] Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma[J]. J Dtsch Dermatol Ges, 2016, 14: 199-216. doi:  10.1111/ddg.12724
    [25] Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea)[J]. J Am Acad Dermatol, 2012, 67: 1151-1156. doi:  10.1016/j.jaad.2012.03.036
    [26] Lythgoe H, Almeida B, Bennett J, et al. Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management[J]. Pediatr Rheumatol Online J, 2018, 16: 80. doi:  10.1186/s12969-018-0295-0
    [27] Asano Y, Fujimoto M, Ishikawa O, et al. Diagnostic criteria, severity classification and guidelines of localized scleroderma[J]. J Dermatol, 2018, 45: 755-780. doi:  10.1111/1346-8138.14161
    [28] Ozgen M, Koca SS, Dagli AF, et al. Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma[J]. Clin Exp Dermatol, 2012, 37: 48-54. doi:  10.1111/j.1365-2230.2011.04201.x
    [29] Mertens JS, Marsman D, van de Kerkhof PC, et al. Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate[J]. Acta Derm Venereol, 2016, 96: 510-513. doi:  10.2340/00015555-2297
    [30] Martini G, Saggioro L, Culpo R, et al. Mycophenolate mofetil for methotrexate-resistant juvenile localized sclero-derma[J]. Rheumatology (Oxford), 2021, 60: 1387-1391. doi:  10.1093/rheumatology/keaa392
    [31] Li SC, Torok KS, Pope E, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma[J]. Arthritis Care Res(Hoboken), 2012, 64: 1175-1185.
    [32] Dytoc M, Wat H, Cheung-Lee M, et al. Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial[J]. J Cutan Med Surg, 2015, 19: 132-139. doi:  10.2310/7750.2014.14072
    [33] Pope E, Doria AS, Theriault M, et al. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study[J]. Dermatology, 2011, 223: 363-369. doi:  10.1159/000335560
    [34] Kroft EB, Groeneveld TJ, Seyger MM, et al. Efficacy of topical tacrolimus 0.1% in active plaque morphea: rando-mized, double-blind, emollient-controlled pilot study[J]. Am J Clin Dermatol, 2009, 10: 181-187. doi:  10.2165/00128071-200910030-00004
    [35] Bali G, Frühauf J, Wutte N, et al. Cyclosporine Reduces Sclerosis in Morphea: a Retrospective Study in 12 Patients and a Literature Review[J]. Dermatology, 2016, 232: 503-510. doi:  10.1159/000448171
    [36] Ogawa T, Okiyama N, Takamuki R, et al. Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin A: A case report and review of the published works[J]. J Dermatol, 2019, 46: 354-357. doi:  10.1111/1346-8138.14801
    [37] Aranegui B, Jiménez-Reyes J. Morphea in Childhood: An Update[J]. Actas Dermosifiliogr (Engl Ed), 2018, 109: 312-322. doi:  10.1016/j.ad.2017.06.021
    [38] Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma[J]. J Am Acad Dermatol, 2000, 43: 1017-1023. doi:  10.1067/mjd.2000.108369
    [39] Frumholtz L, Roux J, Bagot M, et al. Treatment of Generalized Deep Morphea with Everolimus[J]. JAMA Dermatol, 2016, 152: 1170-1172. doi:  10.1001/jamadermatol.2016.2338
    [40] Kumar AB, Blixt EK, Drage LA, et al. Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996—2013[J]. J Am Acad Dermatol, 2019, 80: 1658-1663. doi:  10.1016/j.jaad.2019.01.040
    [41] Inamo Y, Ochiai T. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate[J]. Pediatr Dermatol, 2013, 30: e191-e193. doi:  10.1111/j.1525-1470.2012.01882.x
    [42] Foeldvari I, Anton J, Friswell M, et al. Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients[J]. J Scleroderma Relat Disord, 2017, 2: 203-207. doi:  10.5301/jsrd.5000259
    [43] Lythgoe H, Baildam E, Beresford MW, et al. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma[J]. Rheumatology (Oxford), 2018, 57: 398-401. doi:  10.1093/rheumatology/kex382
    [44] Kalampokis I, Yi BY, Smidt AC. Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review[J]. Semin Arthritis Rheum, 2020, 50: 645-656. doi:  10.1016/j.semarthrit.2020.03.020
    [45] Stausbøl-Grøn B, Olesen AB, Deleuran B, et al. Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases[J]. Acta Derm Venereol, 2011, 91: 686-688. doi:  10.2340/00015555-1136
    [46] Fage SW, Arvesen KB, Olesen AB. Abatacept Improves Skin-score and Reduces Lesions in Patients with Localized Scleroderma: A Case Series[J]. Acta Derm Venereol, 2018, 98: 465-466. doi:  10.2340/00015555-2878
    [47] Li SC, Torok KS, Ishaq SS, et al. Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma[J]. Rheumatology(Oxford), 2021, 60: 3817-3825. doi:  10.1093/rheumatology/keaa873
    [48] Ferguson ID, Weiser P, Torok KS. A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide[J]. Open Rheumatol J, 2015, 9: 30-35. doi:  10.2174/18743129014090100030
    [49] Kim SR, Charos A, Damsky W, et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib[J]. JAAD Case Rep, 2018, 4: 443-445. doi:  10.1016/j.jdcr.2017.12.003
    [50] Chimenti MS, Teoli M, Di Stefani A, et al. Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis[J]. Eur J Dermatol, 2013, 23: 273-274. doi:  10.1684/ejd.2013.1929
    [51] 刘志锋, 赵慧男, 聂绍良. 积雪草苷药理作用及其机制的研究进展[J]. 广东医学, 2009, 30: 649-651. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX200904080.htm

    Liu ZF, Zhao HN, Nie SL. Progress of Study on Pharmaceutical Activities and Mechanisms of Asiaticoside[J]. Guangdong Yixue, 2009, 30: 649-651. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX200904080.htm
    [52] 田菲, 高娟, 张国强. 积雪草苷联合曲尼司特治疗局限性硬皮病疗效观察[J]. 现代中西医结合杂志, 2016, 25: 3649-3651. doi:  10.3969/j.issn.1008-8849.2016.33.001

    Tian F, Gao J, Zhang GQ. Observe on effect of asiaticoside combined with tranilast in treatment of localized scleroderma[J]. Xiandai Zhongxiyi Jiehe Zazhi, 2016, 25: 3649-3651. doi:  10.3969/j.issn.1008-8849.2016.33.001
    [53] 胡南, 肖志平, 温云鹏, 等. 积雪草苷联合曲尼司特治疗局限性硬皮病的临床疗效观察[J]. 皮肤病与性病, 2019, 41: 469-471. https://www.cnki.com.cn/Article/CJFDTOTAL-PFBX201904002.htm

    Hu N, Xiao ZP, Wen YP, et al. Clinical observation of asiaticoside combined with tranilast in the treatment of localized scleroderma[J]. Pifubing Yu Xingbing, 2019, 41: 469-471. https://www.cnki.com.cn/Article/CJFDTOTAL-PFBX201904002.htm
  • 加载中
计量
  • 文章访问数:  569
  • HTML全文浏览量:  64
  • PDF下载量:  60
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-06
  • 录用日期:  2021-03-10
  • 网络出版日期:  2021-12-16
  • 刊出日期:  2022-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!